The Friends of Warminster Hospital intend to work toward getting a new scanner for the healthcare facility, reported This is Wiltshire on September 5.

The scanner will be of benefit to patients who usually have to travel excessive distances to get treatment for their eye issues at other facilities.

(MacularDegenerations.com) According to the article, the OCT eye scanner, which costs  £36,000, is used to monitor age-related macular degeneration (AMD) and glaucoma. However, the closest scanners are at the Royal United Hospital and Salisbury Hospital, which means that people in Warminster are in for a long ride to get necessary scanning treatment. But, if the Friends of Warminster Hospital has the last say, these patients will sooner rather than later be able to have treatments at the area hospital.

Charles Lan, chairman of the  Friends of Warminster Hospital, said in the article that getting the OCT eye scanner would be a great strategy to help the many elderly patients who currently have to travel very long distances on a monthly basis — which can also be dangerous with their compromised vision. He noted that the issue, while a “problem nationally,” is particularly problematic in the “south west” region due to the higher percentage of elderly people living there compared to elsewhere in the country. He added in the article that having an OCT eye scanner at the Warminster Hospital will not only benefit patients who don’t have to travel so far, but also benefit other hospitals that are presently a tad “overburdened” by the increased demand.

According to the article, the Friends of Warminster Hospital are putting their money where their mouth is by ponying up some of the funds needed to acquire the OCT eye scanner. They will also request that the town council, local opticians, the area board and the public make contributions towards the purchase of the machine. According to the article, Friends of Warminster Hospital place donation envelopes around Warminster so that people who want to contribute can do so. Donation envelopes can be found at local surgeries, the hospital, the Civic Centre and the Information Centre.

Warminister, a town situated in Wiltshire, England, sits between Bath and Salisbury.

Reference: http://www.thisiswiltshire.co.uk/news/9911445.Warminster_Friends_eye_up_scanner/

{ 0 comments }

(http://www.MacularDegenerations.com) Many Australians with age-related macular degeneration (AMD) will soon face more out-of-pocket expenses for medications to treat their eye condition, according to The Sydney Morning Herald on September 2.

The article, which looked at the case of 71-year-old Helen Ingleby, noted that the retired woman will face a substantial out-of-pock expense hike to $500 from $100 per month due to new Extended Medicare Safety Net changes. The article noted that the changes will limit the value of government refunds issued to people to compensate for fees that exceed the regular Medicare fees. She will bit hit with the fee hike as of November 1.

According to the article, Ingleby is not alone in her plight as there are currently some 167,000 Australians with AMD. What’s more, there are a further 1 million Australians older than 50 who have AMD symptoms. The blindness-causing eye condition is the country’s leading cause of vision loss. And, according to various reports, the prevalence of AMD is likely to increase as people live longer due to medical advances.

The report cited Ingleby as saying that she, not to mention a lot of other AMD patients, are worried that the cost may be too much to shoulder. She not only wondered how long she will be capable of paying the increased amount for her eye injections, but also stated that many people will be sentenced to “go blind” since they won’t be able to afford treatment at all.

According to the article, Ingleby, who was diagnosed with the eye condition two and a half years back, has the wet form of AMD in her left eye and the dry from of AMD in her right eye. She now gets injections of Lucentis in her eyes.

The article cited Macular Degeneration Foundation CEO Julie Heraghty as saying that two out of 10 patients getting eye injections would, under the funding-cap changes, be on the receiving end of higher out-of-pocket expenses. She explained that the majority of physicians charge less than the $546.05 fee for injections into the eye, which means that their patients would be spared increases to out-of-pocket expenses. She advised patients who will have to pay more to see their doctors for advice on their options.

{ 0 comments }

Burnley Residents Enraged Over County’s Plan to Eliminate Electronic Timetables for Buses

September 5, 2012

(www.MacularDegenerations.com) People living with age-related macular degeneration (AMD) are spitting mad over the fact that local government has apparently thumbed its nose at their request to restore the electronic timetables at the bus station in Burnley, UK, reported the Lancashire Telegraph. According to the article, Gordon Birtwistle, MP of Burnley, backed protesters affiliated with the [...]

Read the full article →

Alcohol Consumption Could Increase AMD Odds

September 4, 2012

(MacularDegenerations.com) While there are studies suggesting that moderate use of alcohol has some medicinal value, those reports are only a drop in the bucket compared to the reports suggesting that imbibing can do more harm than good. A study backed by the American Health Assistance Foundation’s Macular Degeneration Research program looked at alcohol consumption records [...]

Read the full article →

Telescope Implant Surgery Helps Ohio Woman to Regain Sight Lost to AMD

August 28, 2012

(http://www.MacularDegenerations.com) After a surgical procedure that almost seems like it was lifted out of the pages of a futuristic novel, 86-year-old Justine Wise has regained sight that had been lost due to age-related macular degeneration (AMD), reported the Post & Courier on August 21. On July 13, Wise, from Tiffin, Ohio, underwent a surgical procedure [...]

Read the full article →

Researchers Come Up with Prosthetic Device that Gives Blind Mice Close-to-Normal Vision

August 25, 2012

Research into drugs and devices that could help people with age-related macular degeneration (AMD) to regain their lost eyesight is nothing new, but every now and then a significant development gives a new glimmer of hope. Such is the case in an article recently published the Examiner. According to the article, researchers at Cornell University, [...]

Read the full article →

US Seniors Have Better Eyesight than did Counterparts of the Previous Generation

August 24, 2012

(www.MacularDegenerations.com) Seniors living in the United States of America aren’t out of the woods when it comes to eye diseases such as age-related macular degeneration (AMD), but a new study suggests that their eye health is better than was the eye heath of seniors a generation prior. According to an article from the Poughkeepsie Journal, [...]

Read the full article →

Oxford BioMedica, Sanofi Announce Interim Results For Wet AMD Drug

August 21, 2012

(http://www.MacularDegenerations.com) Oxford BioMedica, the Oxford, England-based biopharmaceutical company developing gene-based medicines and therapeutic vaccines, and its partner Sanofi, the Paris, France-based diversified healthcare company, have announced a new development regarding testing of their age-related macular degeneration drug (AMD). In an 8 August press release, Oxford and Sanofi announced an encouraging interim assessment of their RetinoStat [...]

Read the full article →

Apeliotus Vision Science’s Readying AdaptDx Product For Roll Out

August 17, 2012

(www.MacularDegenerations.com) Apeliotus Vision Science is pursuing series A financing worth $4 million in order to advance a product designed to identify the beginning phases of age-related macular degeneration (AMD), reported MEDCITY on August 7. Apeliotus Vision Science Chief Executive Officer John Edwards said in the article focusing on the development that the company is on [...]

Read the full article →

Advanced Cell Technology Treats Another AMD Patient

August 13, 2012

Advanced Cell Technology has announced another development as part of its study focusing on people living with the dry version of age-related macular degeneration, reported the Worcester Telegram & Gazette on August 2. According to the article, the company has used retinal cells resulting from human embryonic stem cells (hESC) to treat yet another patient. [...]

Read the full article →